

Medicare

Reimbursement Information

2023



Questions regarding reimbursement for Lantheus products?

Email: reimbursement@lantheus.com

TABLE OF CONTENTS

1. Basic Reimbursement Background and Settings.....	4 - 5
2. DEFINITY® Hospital Outpatient Setting and Ambulatory Payment Classification (APC) Payments.....	6
3. Hospital Outpatient Claim Form Contrast Echo Example.....	7
4. Full Descriptors: Echo C-codes and Current Procedural Terminology (CPT®) Codes	8
5. DEFINITY® Non Hospital Setting.....	9
6. Echo National Average Payments for Physician Office and Independent Diagnostic Testing Facility (IDTF)	10
7. Indications, Contraindications and Important Safety Information.....	11
8. Full Prescribing Information.....	12 - 14

1. Basic Reimbursement Background and Settings

CPT – Current Procedural Terminology

- American Medical Association's five-digit numeric codes used to report medical procedures and services.

HCPCS - Healthcare Common Procedure Coding System

- Level I HCPCS codes are American Medical Association's Current Procedural Terminology (CPT).
- Level II HCPCS codes are alphanumeric five-digit codes primarily used to identify contrast agents, radiopharmaceuticals, supplies and devices.

HCPCS code for DEFINITY®

- Q9957 Injection, perflutren lipid microspheres, per mL.
- There are two units per vial of DEFINITY®.

C-codes

- Unique, temporary HCPCS codes created by Medicare and used only for hospital outpatients. This is often done when no other appropriate code exists.

Q-codes

- Temporary codes created by Medicare to identify items not assigned a CPT code. Many drugs, supplies and biologicals are assigned Q codes.

NDC codes – National Drug Code

- A unique numeric code to identify drugs. The first segment of numbers identifies the labeler or manufacturer, the second segment identifies the product and the third identifies the package.

NDC codes DEFINITY® and DEFINITY® RT


- DEFINITY® 4 vial kit: NDC # 11994 011 04
- DEFINITY® 16 vial kit: NDC # 11994 011 16
- DEFINITY® RT 20 vial: NDC # 11994 017 20

Echocardiography codes^{1,2}

- **CPT 93306 – TTE “rest” echo complete**
Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography.
- **HCPCS C8929 TTE “rest” echo complete with contrast**
Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography.
- **HCPCS C8929 - CMS “short descriptor”**
TTE w or w/o fol wcon, Doppler

JW modifier - The JW modifier is not required for packaged drugs such as DEFINITY® for Medicare Hospital Outpatients.

Lantheus cannot guarantee coverage or payment for products or procedures. Payer policies can vary widely. For more specific information contact the payer directly in order to obtain up to date coverage, coding and payment information.



2. DEFINITY® Hospital Outpatient Setting and APC Payments³

In the Medicare Hospital Outpatient setting DEFINITY® is reimbursed, however, the payment is packaged with the imaging procedure payment.

CY 2023 national, unadjusted OPPS rates

Please note these are the Calendar Year 2023 national, unadjusted Medicare rates in Hospital Outpatient Payment setting.

93306 TTE complete with Doppler and color flow without contrast \$503.13

C8929 TTE complete with Doppler and color flow with contrast \$740.75

C8929, with contrast, is reimbursed \$237.62 higher than 93306, without contrast, due to the higher cost to perform a contrast echo.

Hospitals must bill for the appropriate C-code when reporting an echo with DEFINITY® in order to receive the packaged payment for DEFINITY®. If a C-code is not billed there will be no payment for contrast. Q9957 is not paid as a separate item.

When billing echo procedures, report the appropriate C-code for an echo with contrast or the appropriate CPT code for an echo without contrast. Do not report both. When using DEFINITY®, hospitals should report Q9957 two units per vial. It is not paid separately but this allows Medicare to collect cost and charge data in order to set future payments.

APCs ECHO PROCEDURES - WITHOUT CONTRAST³

APC 5523 - \$233.52

Level 3 Imaging Without Contrast

93307 TTE complete w/o Doppler and color flow
93308 TTE follow up or limited
(64 total imaging procedure codes in APC 5523)

APC 5524 - \$503.13

Level 4 Imaging Without Contrast

93303 TTE congenital, complete
93304 TTE congenital follow up or limited
93306 TTE complete with Doppler and color flow
93312 TEE include placement, acq, inter, report
93313 TEE placement only
93315 TEE cong, placement, acq, inter, report
93316 TEE congenital placement only
93318 TEE monitor, placement, acq, inter
93350 Stress TTE (w/o ECG monitoring)
93351 Stress TTE (includes ECG monitoring)
(20 total imaging procedure codes in APC 5524)

0439T, 93319 and 93356 are packaged by Medicare and there is no separate payment for hospital outpatients.

APCs ECHO PROCEDURES - WITH CONTRAST³

APC 5572 - \$368.43

Level 2 Imaging With Contrast

C8924 TTE follow up or limited with contrast
(62 total imaging with contrast codes in APC 5572)

APC 5573 - \$740.75

Level 3 Imaging With Contrast

C8921 TTE congenital complete with contrast
C8922 TTE congenital follow up or limited with contrast
C8923 TTE complete w/o Doppler, CF with contrast
C8925 TEE placement, acq, inter, report with contrast
C8926 TEE congenital placement, image, inter, report with contrast
C8927 TEE monitor, placement, acq, inter, w/ contrast
C8928 Stress TTE (no ECG monitoring) with contrast
C8929 TTE comp. with Dop., color flow with contrast
C8930 Stress TTE (with ECG monitoring) with contrast
(22 total Imaging with contrast codes in APC 5573)

For complete code descriptors see page 8

3. Claim Form

1 Anytown Hospital 100 Main St Anytown Anystate										2										3a PAT. CNTL. # b. MED. REC. # 5 FED. TAX NO.										4 TYPE OF BILL																																																																																																																																																																																																																																															
8 PATIENT NAME a Doe, John										9 PATIENT ADDRESS a 123 Maple Ave																																																																																																																																																																																																																																																																			
10 BIRTHDATE xx/xx/1940										11 SEX										12 DATE										13 ADMISSION 13 HR 14 TYPE 15 SRC 16 DHR 17 STAT 18 19 20 21										22 CONDITION CODES 23 24 25 26 27 28 29 ACCT STATE 30																																																																																																																																																																																																																																					
31 OCCURRENCE DATE										32 OCCURRENCE DATE										33 OCCURRENCE DATE										34 OCCURRENCE DATE										35 CODE OCCURRENCE SPAN FROM THROUGH										36 CODE OCCURRENCE SPAN FROM THROUGH										37																																																																																																																																																																																																																	
38										39 CODE VALUE CODES AMOUNT										40 CODE VALUE CODES AMOUNT										41 CODE VALUE CODES AMOUNT																																																																																																																																																																																																																																															
42 REV. CD.										43 DESCRIPTION										44 HCPCS / RATE / HIPPS CODE										45 SERV. DATE										46 SERV. UNITS										47 TOTAL CHARGES										48 NON-COVERED CHARGES										49																																																																																																																																																																																																							
1										TTE echo complete with contrast										C8929										01/05/2022										1										xx xx																				1																																																																																																																																																																																																							
2										peflutren lipid microspheres										Q9957										01/05/2022										2										xx xx																				2																																																																																																																																																																																																							
3																																																																						3																																																																																																																																																																																																							
4																																																																																4																																																																																																																																																																																													
5																																																																																5																																																																																																																																																																																													
6																																																																																6																																																																																																																																																																																													
7																																																																																7																																																																																																																																																																																													
8																																																																																8																																																																																																																																																																																													
9																																																																																9																																																																																																																																																																																													
10																																																																																10																																																																																																																																																																																													
11																																																																																11																																																																																																																																																																																													
12																																																																																12																																																																																																																																																																																													
13																																																																																13																																																																																																																																																																																													
14																																																																																14																																																																																																																																																																																													
15																																																																																15																																																																																																																																																																																													
16																																																																																16																																																																																																																																																																																													
17																																																																																17																																																																																																																																																																																													
18																																																																																18																																																																																																																																																																																													
19																																																																																19																																																																																																																																																																																													
20																																																																																20																																																																																																																																																																																													
21																																																																																21																																																																																																																																																																																													
22																																																																																22																																																																																																																																																																																													
23																																																																																23																																																																																																																																																																																													
PAGE										OF										CREATION DATE										TOTALS																																																																																																																																																																																																																																															
50 PAYER NAME A Medicare										51 HEALTH PLAN ID										52 REL INFO										53 ASG BEN.										54 PRIOR PAYMENTS										55 EST. AMOUNT DUE										56 NPI										57 OTHER										58 INSURED'S NAME										59 P REL										60 INSURED'S UNIQUE ID										61 GROUP NAME										62 INSURANCE GROUP NO.																																																																																																																																																					
B																																																																																																														B																																																																																																																																																															
C																																																																																																																								C																																																																																																																																																					
63 TREATMENT AUTHORIZATION CODES										64 DOCUMENT CONTROL NUMBER										65 EMPLOYER NAME										66 DX										67										68																																																																																																																																																																																																																											
A																																																																																																				A																																																																																																																																																																									
B																																																																																																				B																																																																																																																																																																									
C																																																																																																				C																																																																																																																																																																									
69 ADMIT DX										70 PATIENT REASON DX										71 PPS CODE										72 ECI										73										74 PRINCIPAL PROCEDURE CODE										75										76 ATTENDING NPI										QUAL										77 OPERATING NPI										QUAL										78 OTHER NPI										QUAL										79 OTHER NPI										QUAL																																																																																																																																	
a.										b.										c.										d.										e.										f.										g.										h.										i.										j.										k.										l.										m.										n.										o.										p.										q.										r.										s.										t.										u.										v.										w.										x.										y.										z.																			
80 REMARKS										81 CC a										b										c										d										e										f										g										h										i										j										k										l										m										n										o										p										q										r										s										t										u										v										w										x										y										z									

C-code must be billed in order to obtain reimbursement for the contrast agent combined with the echo procedure. Q9957 will not be paid as a separate line item

Q-code identifies which contrast agent was used.

4. Complete code descriptors. Without contrast left column, with contrast right column

Echo without contrast ¹			Echo with contrast ²	
93303	Transthoracic echocardiography for congenital cardiac anomalies; complete	↔	C8921	Transthoracic echocardiography with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; complete
93304	Transthoracic echocardiography for congenital cardiac anomalies; follow-up or limited study	↔	C8922	Transthoracic echocardiography with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; follow-up or limited study
93306	Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography	↔	C8929	Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography
93307	Echocardiography, transthoracic, real-time, with image documentation (2D), includes M-mode recording, when performed, complete, without spectral or color Doppler echocardiography	↔	C8923	Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2D), includes M-mode recording, when performed, complete, without spectral or color Doppler echocardiography
93308	Echocardiography, transthoracic, real-time, with image documentation (2D), includes M-mode recording, when performed, follow-up or limited study	↔	C8924	Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2D), includes M-mode recording, when performed, follow-up or limited study
93312	Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report	↔	C8925	Transesophageal echocardiography (TEE) with contrast, or without contrast followed by with contrast, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report
93315	Transesophageal echocardiography for congenital cardiac anomalies; including probe placement image acquisition, interpretation and report	↔	C8926	Transesophageal echocardiography (TEE) with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; including probe placement, image acquisition, interpretation and report
93318	Echocardiography, transesophageal (TEE) for monitoring purposes, including probe placement, real-time 2 - dimensional image acquisition and interpretation leading to ongoing (continuous) assessment of (dynamically changing) cardiac pumping function and to therapeutic measures on an immediate time basis	↔	C8927	Transesophageal echocardiography (TEE) with contrast, or without contrast followed by with contrast, for monitoring purposes, including probe placement, real-time 2-dimensional image acquisition and interpretation leading to ongoing (continuous) assessment of (dynamically changing) cardiac pumping function and to therapeutic measures on an immediate time basis
93350	Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report	↔	C8928	Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill bicycle exercise and or pharmacologically induced stress, with interpretation and report
93351	Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with supervision by a physician or other qualified health care professional.	↔	C8930	Transthoracic echocardiography, with contrast, or without contrast followed by with contrast, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with physician supervision
93356	Myocardial strain imaging using speckle tracking-derived assessment of myocardial mechanics (List separately in addition to codes for echocardiography imaging) Add on code. Use in conjunction with 93303, 93304, 93306, 90337, 93308, 93350, 93351. Report once per session.		NA	
NA			0439T	Myocardial perfusion contrast echocardiography, at rest or with stress, for assessment of myocardial ischemia or viability. (List separately in addition to code for primary procedure) Sunset January, 2023. (Use 0439T in conjunction with 93306, 90337, 93308 93350, 93351)

5. DEFINITY® Non Hospital Setting

HCPSC Q9957 Injection, perflutren lipid microspheres, per mL

- Q9957 HCPSC code for DEFINITY®.
- When reporting HCPSC Q9957 there are two units per vial of DEFINITY®.
- Medicare Part B payment for Q4 2022⁴ - \$45.745 per unit (updated quarterly)
- DEFINITY® is a single use vial.

DEFINITY® is reimbursed separately by Medicare Part B in the physician office setting. The payment allowance limits are updated each quarter and listed on the CMS website at <http://www.cms.hhs.gov/McrPartBDrugAvgSalesPrice/>.

Non-Medicare, private payers usually reimburse echo contrast agents separately in the physician office and IDTF setting. It is not unusual for a private payer to reimburse contrast agents at a rate that is higher than Medicare, however, providers must check their contracts and/or contact their private payers to confirm coding, coverage and payment amounts for contrast agents.

DEFINITY® is a single use vial. Medicare allows reimbursement for the amount injected plus the amount discarded for single use vials. For DEFINITY® one mL is equal to one billing unit. The vial contains more than one mL and less than two mLs, therefore there are two units per vial. When reporting drug units providers round up to the next whole unit when a unit of measure is exceeded.

Category III codes such as 0439T are contractor priced by Medicare under the physician fee schedule. Providers should check with their local Medicare Part B contractor for payment amounts and coverage information.

The interpreting physician must perform the test that was ordered by the treating / referring physician or they must contact the treating physician to change the order. However, the interpreting physician can determine the design of the test without notifying the treating physician for such items as the use or non use of contrast.

In the Medicare Benefit Policy Manual Chapter 15 section 80.6.4 - Rules for Testing Facility Interpreting Physician to Furnish Different or Additional Tests it states that⁶:

“Unless specified in the order, the interpreting physician may determine, without notifying the treating physician/practitioner, the parameters of the diagnostic test (e.g., number of radiographic views obtained, thickness of tomographic sections acquired, use or non-use of contrast media)”.

References:

1. American Medical Association CPT
2. American Medical Association HCPSC Level II Professional
3. See addendum B at: <https://www.cms.gov/license/ama?file=/files/zip/2021-nfrm-opps-addenda.zip>
4. <http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/index.html?redirect=/McrPartBDrugAvgSalesPrice/>
5. <https://www.cms.gov/medicare/medicare-fee-service-payment/physicianfeeschedpfs-federal-regulation-notices/cms-1734-f>
6. <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/bp102c15.pdf>

6. 2023 National, Unadjusted Payments in the Physician Office and IDTFS⁵

TC - Technical Component, 26 - Professional Component, G - Global

CPT		Short Descriptor	Payment	CPT		Short Descriptor	Payment
93303	G	TTE limited congenital	\$ 223.32	93315	26	TEE cong. acq, inter, report	\$ 125.38
93303	TC	TTE limited congenital	\$ 162.32				
93303	26	TTE limited congenital	\$ 61.00	93317	26	TEE acq, inter, report only	\$ 87.43
93304	G	TTE limited	\$ 157.58	93318	26	TEE monitoring	\$ 101.32
93304	TC	TTE limited	\$ 121.66	93319	G	3D TEE or congenital TTE	\$ 55.91
93304	26	TTE limited	\$ 35.92				
				93320	G	Doppler echo	\$ 51.17
93306	G	TTE comp, Dop, CF	\$ 198.58	93320	TC	Doppler echo	\$ 33.55
93306	TC	TTE comp, Dop, CF	\$ 130.47	93320	26	Doppler echo	\$ 17.62
93306	26	TTE comp, Dop, CF	\$ 68.11				
93307	G	TTE comp, w/o Dop, CF	\$ 138.60	93321	G	Doppler echo F/U or limited	\$ 25.42
93307	TC	TTE comp, w/o Dop, CF	\$ 95.22	93321	TC	Doppler echo F/U or limited	\$ 18.30
93307	26	TTE comp, w/o Dop, CF	\$ 43.38	93321	26	Doppler echo F/U or limited	\$ 7.12
93308	G	TTE F/U or limited	\$ 99.63	93325	G	Doppler color flow add-on	\$ 23.72
93308	TC	TTE F/U or limited	\$ 74.89	93325	TC	Doppler color flow add-on	\$ 20.67
93308	26	TTE F/U or limited	\$ 24.74	93325	26	Doppler color flow add-on	\$ 3.05
93312	G	TEE place acq,int, rep.	\$ 239.24	93350	G	Stress TTE only	\$ 187.74
93312	TC	TEE place acq,int, rep.	\$ 133.52	93350	TC	Stress TTE only	\$ 119.62
93312	26	TEE place acq,int, rep.	\$ 105.73	93350	26	Stress TTE only	\$ 68.11
93314	G	TEE acq, inter, report	\$ 230.77	93351	G	Stress TTE with exercise	\$ 234.84
93314	TC	TEE acq, inter, report	\$ 141.65	93351	TC	Stress TTE with exercise	\$ 152.83
93314	26	TEE acq, inter, report	\$ 89.12	93351	26	Stress TTE with exercise	\$ 82.01
93356	G	Myocardial strain image - NF	\$ 37.61	93352	G	Use of contrast at stress	\$ 34.23
93356	G	Myocardial strain image - F	\$ 11.52	0439T		Myocardial perfusion echo	Contractor priced

Payment amounts vary from location to location. See CMS physician fee schedule to confirm your local payment amounts at: <https://www.cms.gov/apps/physician-fee-schedule/license-agreement.aspx>

F – Facility, NF – Non-Facility

For complete text for CPT code descriptors see page 8.

7. Indications, Contraindications and Important Safety Information

INDICATIONS

Activated DEFINITY® and DEFINITY® RT (Perflutren Lipid Microsphere) Injectable Suspension are indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

CONTRAINDICATIONS

Do not administer DEFINITY® and DEFINITY® RT to patients with known or suspected hypersensitivity to perflutren lipid microsphere or its components, such as polyethylene glycol (PEG).

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration [see *Warnings and Precautions (5.1)*]. Most serious reactions occur within 30 minutes of administration.

- Assess all patients for the presence of any condition that precludes DEFINITY® and DEFINITY® RT administration [see *Contraindications (4)*].
- Always have resuscitation equipment and trained personnel readily available.

In postmarketing use, rare but serious cardiopulmonary or hypersensitivity reactions have been reported during or shortly following perflutren and PEG-containing microsphere administration [see *Adverse Reactions (6)*]. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions and/or with pre-existing PEG hypersensitivity [see *Adverse Reactions (6.2)*]. It is not always possible to reliably establish a causal relationship to drug exposure due to the presence of underlying conditions.

Please see Full Prescribing Information on **pages 13-18**, including boxed **WARNING** regarding serious cardiopulmonary reactions.

Questions regarding reimbursement for Lantheus products?

Email: reimbursement@lantheus.com



Trademarks, registered or otherwise, are the properties of their respective owner(s).
©2023 Lantheus. All rights reserved. PM-US-DE-0422 1/2023

DEFINITY[®]

VIAL FOR (Perflutren Lipid Microsphere)
 INJECTABLE SUSPENSION

FOR INTRAVENOUS USE

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use DEFINITY safely and effectively. See full prescribing information for DEFINITY.

DEFINITY (Perflutren Lipid Microsphere) Injectable Suspension, for intravenous use

Initial U.S. Approval: 2001

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

See full prescribing information for complete boxed warning

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration (5.1). Most serious reactions occur within 30 minutes of administration.

- Assess all patients for the presence of any condition that precludes DEFINITY administration (4).
- Always have resuscitation equipment and trained personnel readily available.

RECENT MAJOR CHANGES

Dosage and Administration (2.4)	7/2020
Contraindications (4)	4/2021
Warnings and Precautions (5.2)	4/2021

INDICATIONS AND USAGE

DEFINITY is an ultrasound contrast agent indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. (1)

DOSAGE AND ADMINISTRATION

DEFINITY may be injected by either an intravenous (IV) bolus or infusion. The maximum dose is either two bolus doses or one single intravenous infusion. (2.1)

The recommended bolus dose for activated DEFINITY is 10 microliters (microL)/kg of the activated product by intravenous bolus injection within 30 to 60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 microliters (microL)/kg dose followed by a second 10 mL saline flush may be administered 30 minutes after the first injection to prolong contrast enhancement (2.2).

The recommended infusion dose for activated DEFINITY is via an IV infusion of 1.3 mL added to 50 mL of preservative-free saline. The rate of infusion should be initiated at 4 mL/minute, but titrated as necessary to achieve optimal image enhancement, not to exceed 10 mL/minute. (2.2)

DOSAGE FORMS AND STRENGTHS

DEFINITY is supplied as a single patient use 2 mL clear glass vial or RFID-tagged vial containing clear liquid in packages of four (4) and sixteen (16) single patient use vials. (3)

CONTRAINDICATIONS

Do not administer DEFINITY to patients with known or suspected: Hypersensitivity to perflutren lipid microsphere or its components, such as polyethylene glycol (PEG) (4).

WARNINGS AND PRECAUTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred during or following perflutren-containing microsphere administration. (5.1)

Serious acute hypersensitivity reactions have occurred in patients with no prior exposure to perflutren-containing microsphere products, including patients with prior hypersensitivity reaction(s) to PEG (5.2, 6).

Always have cardiopulmonary resuscitation personnel and equipment readily available prior to DEFINITY administration and monitor all patients for acute reactions (5.1, 5.2).

ADVERSE REACTIONS

The most common adverse reactions (≥0.5%) are headache, back/renal pain, flushing, nausea, chest pain, injection site reactions, and dizziness (6).

To report SUSPECTED ADVERSE REACTIONS, contact Lantheus Medical Imaging, Inc. at 1-800-362-2668 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 4/2021

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 Important Administration Instructions
- 2.2 Dosage
- 2.3 Imaging Guidelines
- 2.4 DEFINITY Activation, Preparation and Handling Instructions

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Serious Cardiopulmonary Reactions
- 5.2 Hypersensitivity Reactions
- 5.3 Systemic Embolization
- 5.4 Ventricular Arrhythmia Related to High Mechanical Index

6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- 6.2 Postmarketing Experience

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility

14 CLINICAL STUDIES

- 14.1 Echocardiography
- 14.2 Pulmonary Hemodynamic Effects

16 HOW SUPPLIED/STORAGE AND HANDLING

- 16.1 How Supplied
- 16.2 Storage and Handling

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration [see *Warnings and Precautions* (5.1)]. Most serious reactions occur within 30 minutes of administration.

- Assess all patients for the presence of any condition that precludes DEFINITY administration [see *Contraindications* (4)].
- Always have resuscitation equipment and trained personnel readily available.

1 INDICATIONS AND USAGE

Activated DEFINITY (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

2 DOSAGE AND ADMINISTRATION

2.1 Important Administration Instructions

- DEFINITY is intended for administration only after activation in the VIALMIX or VIALMIX RFID apparatus. Before injection, this product must be activated and prepared according to the instructions outlined below. The VIALMIX or VIALMIX RFID apparatus should be ordered from Lantheus Medical Imaging, 331 Treble Cove Road, North Billerica, MA, 01862. For customer orders call 1-800-299-3431
- DEFINITY may be injected by either an intravenous (IV) bolus or infusion. Do not administer DEFINITY by intra-arterial injection [see *Warnings and Precautions* (5.3)].
- The maximum dose is either two bolus doses or one single intravenous infusion. The safety of bolus and infusion dosing in combination or in sequence, has not been studied.

2.2 Dosage

Bolus

The recommended bolus dose for activated DEFINITY is 10 microliters (microL)/kg of the activated product by intravenous bolus injection within 30 to 60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 microliters (microL)/kg dose followed by a second 10 mL saline flush may be administered 30 minutes after the first injection to prolong contrast enhancement.

Infusion

The recommended infusion dose for activated DEFINITY is via an IV infusion of 1.3 mL added to 50 mL of preservative-free saline. The rate of infusion should be initiated at 4 mL/minute, but titrated

as necessary to achieve optimal image enhancement, not to exceed 10 mL/minute.

2.3 Imaging Guidelines

After baseline non-contrast echocardiography is completed, set the mechanical index for the ultrasound device at 0.8 or below [see *Warnings and Precautions* (5.4)]. Then inject activated DEFINITY (as described above) and begin ultrasound imaging immediately. Evaluate the activated DEFINITY echocardiogram images in combination with the non-contrast echocardiogram images.

In a crossover trial of 64 patients randomized to both bolus and infusion, the duration of clinically useful contrast enhancement for fundamental imaging was approximately 3.4 minutes after a 10 microL/kg bolus and was approximately 7.1 minutes during the continuous infusion of 1.3 mL activated DEFINITY in 50 mL saline at a rate of 4 mL/min.

2.4 DEFINITY Activation, Preparation and Handling Instructions

Follow directions for activation of DEFINITY carefully and adhere to strict aseptic procedures during preparation.

1. Allow the vial to warm to room temperature before starting the activation procedure.
2. Activate DEFINITY by shaking the vial for 45 seconds using a VIALMIX device or VIALMIX RFID device.

Note: illustrations of this procedure are contained in the VIALMIX or VIALMIX RFID User's Guide.

Do not use this drug unless it has completed a full 45 second activation cycle in the VIALMIX or VIALMIX RFID. DEFINITY will not be properly activated unless the full 45 second activation cycle is completed. Error messages will display if the vial is not properly activated. Do not reactivate the vial if VIALMIX or VIALMIX RFID did not properly activate the vial. Never reactivate a successfully activated DEFINITY vial (see step 3). A VIALMIX or VIALMIX RFID that is not functioning properly must never be used. Only use a vial activated from a properly functioning VIALMIX or VIALMIX RFID. Refer to the VIALMIX or VIALMIX RFID User's Guide to ensure that a properly functioning VIALMIX or VIALMIX RFID is used.

3. Immediately after activation in the VIALMIX or VIALMIX RFID, activated DEFINITY appears as a milky white suspension and may be used immediately after activation. If the product is not used within 5 minutes of activation, the microspheres should be resuspended by 10 seconds of hand agitation by inverting the vial before the product is withdrawn in a syringe. The activated DEFINITY may be used for up to 12 hours from the time of activation, but only after the microspheres are resuspended by hand agitation. Store the activated DEFINITY at room temperature in the original product vial.
4. Invert the vial and withdraw the activated milky white suspension using the Intellipin (Dispensing Pin), the PINSYNC (Vented Vial Adapter 13mm), or 18 to 20 gauge syringe needle. Withdraw the material from the middle of the liquid in the inverted vial. Do not inject air into the DEFINITY Vial.
5. Use the product immediately after its withdrawal from the vial; do not allow the product to stand in the syringe.

Special Instructions for the DEFINITY Radio Frequency Identification (RFID)-Tagged Vial

This information is for vials containing DEFINITY that have been labeled with a Radio Frequency Identification (RFID) tag. Full instructions for use of VIALMIX RFID are provided on the VIALMIX RFID screen and User's Guide.

- The RFID tag allows for the exchange of product information such as activation time and activation rate.
- VIALMIX RFID will only activate DEFINITY RFID-tagged vials. Function of the RFID technology is not dependent on vial orientation as it is placed in the VIALMIX RFID. If the RFID tag is damaged or otherwise non-functional, the VIALMIX RFID will notify the user and the vial with the non-functional RFID tag cannot be used to activate DEFINITY with VIALMIX RFID. Discard the non-functional RFID-tagged DEFINITY vial.
- Follow all manufacturers' guidelines and do not operate any part of the VIALMIX RFID with DEFINITY RFID-tagged vials within 6 inches (15 cm) of a pacemaker and/or defibrillator.

3 DOSAGE FORMS AND STRENGTHS

DEFINITY is supplied as a single patient use 2 mL clear glass vial or RFID-tagged vial containing a clear liquid in packages of four (4) and sixteen (16) single patient use vials.

Prior to activation, the headspace of each vial contains 6.52 mg/mL octafluoropropane and the clear liquid contains 0.75mg/mL of a lipid blend. After activation, each vial contains a maximum of 1.2 X 10¹⁰ perflutren lipid microspheres, and about 150 microL/mL (1.1 mg/mL) octafluoropropane [see *Description* (11)].

4 CONTRAINDICATIONS

Do not administer DEFINITY to patients with known or suspected:

- Hypersensitivity to perflutren lipid microsphere or its components, such as polyethylene glycol (PEG) [see Warnings and Precautions (5.2) and Description (11)].

5 WARNINGS AND PRECAUTIONS

5.1 Serious Cardiopulmonary Reactions

Serious cardiopulmonary reactions including fatalities have occurred uncommonly during or shortly following perflutren-containing microsphere administration, typically within 30 minutes of administration. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias). Always have cardiopulmonary resuscitation personnel and equipment readily available prior to DEFINITY administration and monitor all patients for acute reactions.

The reported reactions include: fatal cardiac or respiratory arrest, shock, syncope, symptomatic arrhythmias (atrial fibrillation, tachycardia, bradycardia, supraventricular tachycardia, ventricular fibrillation, ventricular tachycardia), hypertension, hypotension, dyspnea, hypoxia, chest pain, respiratory distress, stridor, wheezing, loss of consciousness, and convulsions [see Adverse Reactions (6)].

5.2 Hypersensitivity Reactions

In postmarketing use, serious hypersensitivity reactions were observed during or shortly following perflutren-containing microsphere administration including:

Anaphylaxis, with manifestations that may include death, shock, bronchospasm, throat tightness, angioedema, edema (pharyngeal, palatal, mouth, peripheral, localized), swelling (face, eye, lip, tongue, upper airway), facial hypoesthesia, rash, urticaria, pruritus, flushing, and erythema.

These reactions have occurred in patients with no prior exposure to perflutren-containing microsphere products. DEFINITY contains PEG. There may be increased risk of serious reactions including death in patients with prior hypersensitivity reaction(s) to PEG [see Adverse Reactions (6.2) and Description (11)]. Clinically assess patients for prior hypersensitivity reactions to products containing PEG, such as certain colonoscopy bowel preparations and laxatives. Always have cardiopulmonary resuscitation personnel and equipment readily available prior to DEFINITY administration and monitor all patients for hypersensitivity reactions.

5.3 Systemic Embolization

When administering DEFINITY to patients with a cardiac shunt, the microspheres can bypass filtering by the lung and enter the arterial circulation. Assess patients with shunts for embolic phenomena following DEFINITY administration. DEFINITY is only for intravenous administration; do not administer DEFINITY by intra-arterial injection [see Dosage and Administration (2.1)].

5.4 Ventricular Arrhythmia Related to High Mechanical Index

High ultrasound mechanical index values may cause microsphere cavitation or rupture and lead to ventricular arrhythmias. Additionally, end-systolic triggering with high mechanical indices has been reported to cause ventricular arrhythmias. DEFINITY is not recommended for use at mechanical indices greater than 0.8 [see Dosage and Administration (2)].

6 ADVERSE REACTIONS

The following serious adverse reactions are described elsewhere in the labeling:

- Serious Cardiopulmonary Reactions [see Warnings and Precautions (5.1)]
- Hypersensitivity Reactions [see Warnings and Precautions (5.2)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

A total of 1716 subjects were evaluated in pre-market clinical trials of activated DEFINITY. In this group, 1063 (61.9%) were male and 653 (38.1%) were female, 1328 (77.4%) were White, 258 (15.0%) were Black, 74 (4.3%) were Hispanic, and 56 (3.3%) were classified as other racial or ethnic groups. The mean age was 56.1 years (range 18 to 93). Of these, 144 (8.4%) had at least one adverse reaction (Table 1). There were 26 serious adverse events and 15 (0.9%) subjects discontinued because of an adverse event.

Serious Adverse Reactions

Among the 1716 study patients, 19 (1.1%) suffered serious cardiopulmonary adverse reactions.

For all adverse reactions, the overall incidence of adverse experiences was similar for the <65 year age group and the > 65 year age group, similar in males and in females, similar among all racial or ethnic groups, and similar for bolus and infusion dosing. Table 1 summarizes the most common adverse reactions.

Table 1 New-Onset Adverse Reactions Occurring in ≥0.5% of All DEFINITY-Treated Subjects

	DEFINITY (N=1716)	
Total Number of Adverse Reactions	269	
Total Number of Subjects with an Adverse Reaction	144	(8.4%)
Body system		
Preferred term	n	(%)
Application Site Disorders	11	(0.6)
Injection Site Reactions	11	(0.6)
Body as a Whole	41	(2.4)
Back/renal pain	20	(1.2)
Chest pain	13	(0.8)
Central and peripheral nervous system disorder	54	(3.1)
Headache	40	(2.3)
Dizziness	11	(0.6)
Gastrointestinal system	31	(1.8)
Nausea	17	(1.0)
Vascular (extracardiac) disorders	19	(1.1)
Flushing	19	(1.1)

N=Sample size 1716 subjects who received activated DEFINITY
n=Number of subjects reporting at least one Adverse Reaction

Other adverse reactions that occurred in ≤0.5% of the activated DEFINITY-dosed subjects were:

Body as a Whole: Fatigue, fever, hot flushes, pain, rigors, and syncope

Cardiovascular: Abnormal ECGs, bradycardia, tachycardia, palpitation, hypertension and hypotension

Digestive: Dyspepsia, dry mouth, tongue disorder, toothache, abdominal pain, diarrhea and vomiting

Hematology: Granulocytosis, leukocytosis, leukopenia, and eosinophilia

Musculoskeletal: Arthralgia

Nervous System: Leg cramps, hypertonia, vertigo and paresthesia

Platelet, Bleeding, and Clotting: Hematoma

Respiratory: Coughing, hypoxia, pharyngitis, rhinitis and dyspnea

Special Senses: Decreased hearing, conjunctivitis, abnormal vision and taste perversion

Skin: Pruritus, rash, erythematous rash, urticaria, increased sweating, and dry skin

Urinary: Albuminuria

6.2 Postmarketing Experience

In a prospective, multicenter, open-label registry of 1053 patients receiving DEFINITY in routine clinical practice, heart rate, respiratory rate, and pulse oximetry were monitored for 30 minutes after DEFINITY administration. No deaths or serious adverse reactions were reported, suggesting that these reactions are unlikely to occur at a rate of more than 0.3% when DEFINITY is used according to recommendations.

The following adverse reactions have been identified during the post-marketing use of perflutren and PEG-containing microsphere products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Fatal cardiopulmonary and hypersensitivity reactions and other serious but non-fatal adverse reactions were uncommonly reported. These reactions typically occurred within 30 minutes of DEFINITY administration. These serious reactions may be increased among patients with pre-existing PEG hypersensitivity and/or unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias [see Warnings and Precautions (5.1, 5.2)].

Reported reactions included:

Cardiopulmonary

Fatal cardiac or respiratory arrest, shock, syncope, symptomatic arrhythmias (atrial fibrillation, tachycardia, bradycardia, supraventricular tachycardia, ventricular fibrillation, ventricular tachycardia), hypertension, hypotension, dyspnea, hypoxia, chest pain, respiratory distress, stridor, wheezing.

Hypersensitivity

Anaphylaxis, with manifestations that may include death, shock, bronchospasm, throat tightness, angioedema, edema (pharyngeal, palatal, mouth, peripheral, localized), swelling (face, eye, lip, tongue, upper airway), facial hypoesthesia, rash, urticaria, pruritus, flushing, and erythema.

Neurologic

Coma, loss of consciousness, convulsion, seizure, transient ischemic attack, agitation, tremor, vision blurred, dizziness, headache, fatigue.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Available data from case reports with DEFINITY use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. DEFINITY has a very short half-life; therefore, administration of DEFINITY to a pregnant woman is not expected to result in clinically relevant fetal exposure. No adverse developmental outcomes were observed in animal reproduction studies with administration of activated DEFINITY in pregnant rats and rabbits during organogenesis at doses up to 8 and 16 times, respectively, the maximum human dose based on body surface area (see Data).

All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data

Animal Data

DEFINITY was administered intravenously to rats at doses of 0.1, 0.3, and 1.0 mL/kg (approximately 0.8, 2.4, and 8 times the recommended maximum human dose based on body surface area); DEFINITY doses were administered daily from day 6 to day 17 of gestation. DEFINITY was administered intravenously to rabbits at doses of 0.1, 0.3, and 1.0 mL/kg (approximately, 1.6, 4.8, and 16 times the recommended maximum human dose based on body surface area); DEFINITY doses were administered daily from day 7 to day 19 of gestation. No significant findings on the fetus were observed.

8.2 Lactation

Risk Summary

There are no data on the presence of DEFINITY in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for DEFINITY and any potential adverse effects on the breastfed infant from DEFINITY or from the underlying maternal condition.

8.4 Pediatric Use

The safety and effectiveness of activated DEFINITY have not been established in the pediatric population.

The safety of injecting activated DEFINITY in neonates and infants with immature pulmonary vasculature has not been studied.

The pharmacokinetics of activated DEFINITY in pediatric subjects has not been studied.

8.5 Geriatric Use


In clinical trials, the overall incidence of adverse reactions was similar for the <65 year age group and the ≥65 year age group. Of the total number of subjects in clinical trials of DEFINITY, 144 (33%) were 65 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

11 DESCRIPTION


DEFINITY (Perflutren Lipid Microsphere) Injectable Suspension is an ultrasound contrast agent. The DEFINITY vial contains components that upon activation yield perflutren lipid microspheres. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic liquid, which upon activation with the aid of a VIALMIX or VIALMIX RFID, provides a homogeneous, opaque, milky white injectable suspension of perflutren lipid microspheres. The suspension of activated DEFINITY is administered by intravenous injection.

The perflutren lipid microspheres are composed of octafluoropropane encapsulated in an outer lipid shell consisting of (R) - hexadecanoic acid, 1-[(phosphonoxy)methyl]-1,2-ethanediyl ester, monosodium salt (abbreviated DPPA); (R) - 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-3,4,9-trioxa-4-phosphapentacosan-1-aminium, 4-oxide, inner salt (abbreviated DPPC); and (R)-α-[6-hydroxy-6-oxido-9-[(1-oxohexadecyl)oxy]-5,7,11-trioxa-2-aza-6-phosphahexacos-1-yl]-ω-methoxy-poly(ox-1,2-ethanediyl), monosodium salt; commonly called N-(methoxypropyl)ethylene glycol 5000 carbamoyl-1,2-dipalmitoyl-sn-glycero-3- phosphatidylethanolamine, monosodium salt (abbreviated MPEG5000 DPPE).


Octafluoropropane is chemically characterized as 1,1,1,2,2,3,3,3-octafluoropropane. It has a molecular weight of 188, empirical formula of C₃F₈ and has the following structural formula:




DPPA has a molecular weight of 670, empirical formula of C₃₅H₆₈O₈PNa, and following structural formula:



DPPC has a molecular weight of 734, empirical formula of C₄₀H₈₀N₂O₈P and following structural formula:



MPEG5000 DPPE has an approximate molecular weight of 5750 represented by empirical formula C₂₆₅H₅₂₇NO₁₂₄PNa, contains <100ppm Ca+2 and Mg+2 and the following structural formula:



Prior to activation, the DEFINITY vial contains 6.52 mg/mL octafluoropropane in the headspace which was required to be confirmed by positive IR spectroscopic testing in every vial. Each mL of the clear liquid contains 0.75 mg lipid blend (consisting of 0.045 mg DPPA, 0.401 mg DPPC, and 0.304 mg MPEG5000 DPPE), 103.5 mg propylene glycol, 126.2 mg glycerin, 2.34 mg sodium phosphate monobasic monohydrate, 2.16 mg sodium phosphate dibasic heptahydrate, and 4.87 mg sodium chloride in Water for Injection. The pH is 6.2-6.8. DEFINITY does not contain bacterial preservative.

After activating the contents of the DEFINITY vial, each mL of the milky white suspension contains a maximum of 1.2 X 10¹⁰ perfluten lipid microspheres, and about 150 microL/mL (1.1 mg/mL) octafluoropropane. The microsphere particle size parameters are listed in Table 2 below:

Table 2 Microsphere Size Distribution	
Microsphere particle size parameters	
Mean diameter range	1.1 µm – 3.3 µm
Percent less than 10 µm	98%
Maximum diameter	20 µm

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Perfluten lipid microspheres exhibit lower acoustic impedance than blood and enhance the intrinsic backscatter of blood. These physical acoustic properties of activated DEFINITY provide contrast enhancement of the left ventricular chamber and aid delineation of the left ventricular endocardial border during echocardiography.

In animal models the acoustic properties of activated DEFINITY were established at or below a mechanical index of 0.7 (1.8 MHz frequency). In clinical trials, the majority of the patients were imaged at or below a mechanical index of 0.8.

12.3 Pharmacokinetics

Human pharmacokinetics information is not available for the intact or degassed lipid microspheres. The pharmacokinetics of octafluoropropane gas (OFP) was evaluated in healthy subjects (n=8) after the IV administration of activated DEFINITY at a 50 microL/kg dose.

Distribution

OFP gas binding to plasma proteins or partitioning into blood cells has not been studied. However, OFP protein binding is expected to be minimal due to its low partition coefficient into whole blood.

Metabolism

OFP is a stable gas that is not metabolized. The phospholipid components of the microspheres are thought to be metabolized to free fatty acids.

Elimination

OFP was not detectable after 10 minutes in most subjects either in the blood or in expired air. OFP concentrations in blood were shown to decline in a mono-exponential fashion with a mean half-life of 1.3 minutes in healthy subjects.

Special Populations

The pharmacokinetics of octafluoropropane gas (OFP) was evaluated in subjects (n=11) with chronic obstructive pulmonary

disease (COPD). The mean half-life of OFP in blood was 1.9 minutes. The total lung clearance of OFP was similar to that in healthy subjects.

The pharmacokinetics of activated DEFINITY has not been studied in subjects with hepatic diseases or congestive heart failure.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility

Studies with activated DEFINITY have not been performed to evaluate carcinogenic potential. Evidence of genotoxicity was not found in the following studies with activated DEFINITY: 1) bacterial mutagenesis assay (Ames assay), 2) *in vitro* mammalian mutagenesis assay, 3) *in vitro* human lymphocyte chromosome aberration assay, and 4) *in vivo* rat micronucleus assay.

Impairment of male or female fertility was not observed in rats and rabbits treated with activated DEFINITY at doses up to 24 and 15 times the human dose based on body surface area (in rats and rabbits respectively).

14 CLINICAL STUDIES

14.1 Echocardiography

A total of 249 subjects were evaluated in clinical trials (208 received activated DEFINITY and 41 placebo). In this group, 154 (61.8%) were male and 95 (38.2%) were female; 183 (73.5%) were White, 38 (15.3%) were Black, 21 (8.4%) were Hispanic, and 7 (2.8%) were classified as other racial or ethnic groups. The mean age was 53.9 years (range 18 to 87).

Activated DEFINITY was evaluated in four controlled clinical trials: Two open-label baseline controlled, unpaired blinded image evaluation studies and two identical placebo-controlled, unpaired blinded image evaluation studies. Subjects were eligible for these studies if they had two or more (of six) non-evaluable segments in either the apical 2- or 4-chamber view in non-contrast fundamental echocardiography.

In the baseline controlled studies, a total of 126 (67 in study A and 59 in study B) subjects received a bolus dose of 10 microL/kg activated DEFINITY. The outcome measures in these studies included the blinded assessment of ejection fraction (EF), endocardial border length (EBL) obtained by direct measurement, and qualitative assessment of wall motion.

In the two placebo-controlled studies a total of 123 subjects were randomized in 1:2 ratio to receive two IV bolus doses of either saline (placebo) or activated DEFINITY 10 microL/kg (17 placebo vs. 33 activated DEFINITY patients and 24 placebo vs. 49 activated DEFINITY patients, respectively). The outcome measure for assessing the effectiveness of activated DEFINITY was the blinded assessment of improvement in ventricular chamber enhancement (measured by videodensitometry at end-diastole and end-systole).

Endocardial Border Length

As shown in Table 3, compared to baseline, a single bolus dose of 10 microL/kg of activated DEFINITY increased the length of endocardial border that could be measured at both end-systole and end-diastole. The mean change in border length from baseline at end-diastole was statistically significant for all readers in the apical 4-chamber view and for 3 out of 4 readers for the apical 2-chamber view. The mean change in border length from baseline at end-systole was statistically significant for 3 out of 4 readers for the apical 4-chamber view and for 2 out of 4 readers for the apical 2-chamber view.

Ventricular Chamber Enhancement

Left ventricular chamber enhancement after an activated DEFINITY dose of 10 microL/kg was significantly increased from baseline compared to placebo in both views at the mid-ventricular and apical levels at end-diastole. Similar results were noted at end-systole, with the exception of the 4-chamber view.

Wall Motion

In a retrospective analysis, in a subset of subjects (n=12 to 47, depending on reader) having at least 2 adjacent segments non-evaluable on non-contrast imaging, activated DEFINITY converted a baseline non-evaluable image to an evaluable image in 58 to 91% of the patients, depending on the reader. In the converted images, the accuracy of wall motion (i.e., normal versus abnormal) improved in 42 to 71% of the patients, depending on the reader, however, improvement in the specific diagnostic accuracy (e.g., hypokinetic, akinetic etc.) was not established. Also, in 13 to 37% of the patients, depending on the reader, activated DEFINITY was found to obscure the wall motion rendering the image non-evaluable.

Ejection Fraction

In the 2 baseline controlled studies, ejection fraction results were evaluated in comparison to MRI. The results were evaluated by 3 blinded, independent radiologists. In these studies, although there was a statistically significant increase in ventricular chamber enhancement, activated DEFINITY did not significantly improve the assessment of ejection fraction compared to the baseline images.

Table 3 MEAN (SD) ENDOCARDIAL BORDER LENGTH (CM) BY BOTH APICAL 2- AND 4-CHAMBER VIEWS AT END-SYSTOLE AND END-DIASTOLE BY STUDY, EVALUABLE SUBJECTS

Study/View	Endocardial Border Length – Blinded Read			
	Mean(SD) at End-Diastole		Mean(SD) at End-Systole	
	Reader 1	Reader 2	Reader 1	Reader 2
Study A: (N = 67)				
Apical 2-chamber				
Baseline	8.0(3.4)	4.7(2.8)	7.1(3.3)	4.3(2.6)
Post-DEFINITY	12.8(5.2)*	5.8(2.6)*	10.6(5.0)*	4.4(2.3)
Apical 4-chamber				
Baseline	8.1(3.3)	4.5(2.6)	7.6(3.2)	4.5(2.7)
Post-DEFINITY	13.5(5.2)*	6.8(3.3)*	11.5(4.4)*	5.3(3.1)
Study B: (N = 59)				
Apical 2-chamber				
Baseline	4.3(2.6)	7.8(5.3)	4.1(2.4)	6.5(5.1)
Post-DEFINITY	5.7(4.7)*	8.2(6.5)	5.5(4.4)*	6.9(6.3)
Apical 4-chamber				
Baseline	4.0(2.7)	9.2(5.9)	3.8(2.6)	7.3(5.6)
Post-DEFINITY	7.1(5.5)*	11.5(7.5)*	5.9(5.3)*	8.7(6.3)*
Activated DEFINITY Bolus Dose = 10 µL/kg				
* Significant change from baseline (paired t-test, p<0.05)				

In an open administration, crossover trial, 64 patients were randomized to receive both bolus (10 microL/kg) and infusion (1.3 mL activated DEFINITY in 50 mL saline at the rate of 4 mL/min) dosing of activated DEFINITY. Outcome measures for this study included clinically useful ventricular cavity enhancement and endocardial border length. Similar results were seen as described above.

Optimal activated DEFINITY doses and device settings for harmonic imaging have not been established.

14.2 Pulmonary Hemodynamic Effects

The impact of DEFINITY on pulmonary hemodynamics was explored in a prospective, open-label study of patients with normal (≤ 35 mmHg, 16 patients) and elevated (> 35 mmHg, < 75 mmHg, 16 patients) pulmonary artery systolic pressure undergoing right heart catheterization. Patients with pulmonary artery systolic pressure greater than 75 mmHg were excluded from this study. Systemic hemodynamic parameters and ECGs were also evaluated. No clinically important pulmonary hemodynamic, systemic hemodynamic, or ECG changes were observed. This study did not assess the effect of DEFINITY on visualization of cardiac or pulmonary structures.

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

DEFINITY is supplied as a single patient use 2 mL clear glass vial or a single patient use 2 mL clear glass Radio Frequency Identification (RFID)-tagged vial containing clear liquid in packages of four (4) and sixteen (16) single patient use vials.

- One (1) 2 mL vial or 2 mL RFID-tagged vial NDC (11994-011-01)
- Four (4) 2 mL vials or 2 mL RFID-tagged vials per kit - NDC (11994-011-04)
- Sixteen (16) 2 mL vials or 2 mL RFID-tagged vials per kit - NDC (11994-011-16)

16.2 Storage and Handling

Store between 2° to 8°C (36° to 46°F).

Regarding interference with medical devices, the RFID tag and VIAL-MIX RFID unit meets the IEC 60601-1-2 requirements for emission and immunity standards for medical devices.

17 PATIENT COUNSELING INFORMATION

Advise patients to inform their healthcare provider if they develop any symptoms of hypersensitivity after DEFINITY administration, including rash, wheezing, or shortness of breath.

Distributed By
Lantheus Medical Imaging
331 Treble Cove Road
N. Billerica, Massachusetts 01862 USA



For ordering, call toll free: 800-299-3431
All Other Business: 800-362-2668
(For Massachusetts and International, call: 978-667-9531)
Patent: <http://www.lantheus.com/patents/index.html>

515987-0221

DEFINITY[®] RT

(Perflutren Lipid Microsphere)
INJECTABLE SUSPENSION

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use DEFINITY safely and effectively. See full prescribing information for DEFINITY.

DEFINITY RT (Perflutren Lipid Microsphere) Injectable Suspension, for intravenous use

Initial U.S. Approval: 2001

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

See full prescribing information for complete boxed warning

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration (5.1). Most serious reactions occur within 30 minutes of administration.

- Assess all patients for the presence of any condition that precludes DEFINITY RT administration (4).
- Always have resuscitation equipment and trained personnel readily available.

RECENT MAJOR CHANGES

Contraindications (4) 4/2021
Warnings and Precautions (5.2) 4/2021

INDICATIONS AND USAGE

DEFINITY RT is an ultrasound contrast agent indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. (1)

DOSAGE AND ADMINISTRATION

DEFINITY RT may be injected by either an intravenous bolus or infusion. The maximum dose is either two bolus doses or one single intravenous infusion. (2.1)

The recommended bolus dose for activated DEFINITY RT is 10 microliters (microL)/kg of the activated product by intravenous bolus injection within 30 to 60 seconds, followed by a 10 mL 0.9% Sodium Chloride Injection, USP flush. If necessary, a second 10 microliters (microL)/kg dose followed by a second 10 mL 0.9% Sodium Chloride Injection, USP flush may be administered 30 minutes after the first injection to prolong contrast enhancement. (2.2)

The recommended infusion dose for activated DEFINITY RT is via an intravenous infusion of 1.3 mL added to 50 mL of preservative-free 0.9% Sodium Chloride Injection, USP. The rate of infusion should be initiated at 4 mL/minute, but titrated as necessary to achieve optimal image enhancement, not to exceed 10 mL/minute. (2.2)

See Full Prescribing Information for instructions on preparation and administration.

DOSAGE FORMS AND STRENGTHS

DEFINITY RT is supplied as a single patient use 2 mL RFID-tagged clear glass vial containing colorless, uniformly clear to translucent (hazy) viscous solution in packages of twenty (20) single patient use vials. (3)

CONTRAINDICATIONS

Do not administer DEFINITY RT to patients with known or suspected: Hypersensitivity to perflutren lipid microsphere or its components, such as polyethylene glycol (PEG) (4).

WARNINGS AND PRECAUTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred during or following perflutren-containing microsphere administration. (5.1)

Serious acute hypersensitivity reactions have occurred in patients with no prior exposure to perflutren-containing microsphere products, including patients with prior hypersensitivity reaction(s) to PEG (5.2, 6).

Always have cardiopulmonary resuscitation personnel and equipment readily available prior to DEFINITY RT administration and monitor all patients for acute reactions (5.1, 5.2).

ADVERSE REACTIONS

The most common adverse reactions ($\geq 0.5\%$) are headache, back/renal pain, flushing, nausea, chest pain, injection site reactions, and dizziness (6).

To report SUSPECTED ADVERSE REACTIONS, contact Lantheus Medical Imaging, Inc. at 1-800-362-2668 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 4/2021

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- Important Administration Instructions
- Dosage
- Imaging Guidelines
- DEFINITY RT Activation, Preparation and Handling Instructions

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- Serious Cardiopulmonary Reactions
- Hypersensitivity Reactions
- Systemic Embolization
- Ventricular Arrhythmia Related to High Mechanical Index

6 ADVERSE REACTIONS

- Clinical Trials Experience
- Postmarketing Experience

8 USE IN SPECIFIC POPULATIONS

- Pregnancy
- Lactation
- Pediatric Use
- Geriatric Use

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- Mechanism of Action
- Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- Carcinogenesis, Mutagenesis, and Impairment of Fertility

14 CLINICAL STUDIES

- Echocardiography
- Pulmonary Hemodynamic Effects

16 HOW SUPPLIED/STORAGE AND HANDLING

- How Supplied
- Storage and Handling

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration.

- Assess all patients for the presence of any condition that precludes DEFINITY RT administration [see Contraindications (4)].
- Always have resuscitation equipment and trained personnel readily available.

1 INDICATIONS AND USAGE

Activated DEFINITY RT (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

2 DOSAGE AND ADMINISTRATION

2.1 Important Administration Instructions

- DEFINITY RT is intended for administration only after activation in the VIALMIX RFID apparatus. Before injection, this product must be activated, diluted, and prepared according to the instructions outlined below. The VIALMIX RFID apparatus should be ordered from Lantheus Medical Imaging, 331 Treble Cove Road, North Billerica, MA, 01862. For customer orders call 1-800-299-3431.
- 13mm ViaLok (packaged separately) must be used in the dilution process of Definity RT
- DEFINITY RT may be injected by either an intravenous bolus or infusion. Do not administer DEFINITY RT by intra-arterial injection [see Warnings and Precautions (5.3)].
- The maximum dose is either two bolus doses or one single intravenous infusion. The safety of bolus and infusion dosing in combination or in sequence, has not been studied.

2.2 Dosage

Bolus

The recommended bolus dose for activated DEFINITY RT is 10 microliters (microL)/kg of the activated product by intravenous bolus injection within 30 to 60 seconds, followed by a 10 mL 0.9% Sodium Chloride Injection, USP flush. If necessary, a second 10 microliters (microL)/kg dose followed by a second 10 mL 0.9% Sodium Chloride Injection, USP flush may be administered 30 minutes after the first injection to prolong contrast enhancement.

Infusion

The recommended infusion dose for activated DEFINITY RT is via an intravenous infusion of 1.3 mL added to 50 mL of preservative-free 0.9% Sodium Chloride Injection, USP. The rate of infusion should be initiated at 4 mL/minute, but titrated as necessary to achieve optimal image enhancement, not to exceed 10 mL/minute.

2.3 Imaging Guidelines

After baseline non-contrast echocardiography is completed, set the mechanical index for the ultrasound device at 0.8 or below [see Warnings and Precautions (5.4)]. Then inject activated DEFINITY RT (as described above) and begin ultrasound imaging immediately. Evaluate the activated DEFINITY RT echocardiogram images in combination with the non-contrast echocardiogram images.

In a crossover trial of 64 patients randomized to both bolus and infusion using DEFINITY, the duration of clinically useful contrast enhancement for fundamental imaging was approximately 3.4 minutes after a 10 microL/kg bolus and was approximately 7.1 minutes during the continuous infusion of 1.3 mL activated DEFINITY in 50 mL 0.9% Sodium Chloride Injection, USP at a rate of 4 mL/min.

2.4 DEFINITY RT Activation, Preparation and Handling Instructions

There are two formulations of perflutren lipid microspheres that have differences concerning storage and preparation. Follow the preparation and storage procedures, as well as directions for activation of DEFINITY RT carefully and adhere to strict aseptic procedures during preparation.

- Activate DEFINITY RT by shaking the vial for 45 seconds using a VIALMIX RFID device.

Note: illustrations of this procedure are contained in the VIALMIX RFID User's Guide.

Do not use this drug unless it has completed a full 45 second activation cycle in the VIALMIX RFID. DEFINITY RT will not be properly activated unless the full 45 second activation cycle is completed. Error messages will display if the vial is not properly activated. Do not reactivate the vial if VIALMIX RFID did not properly activate the vial. Never reactivate a successfully activated DEFINITY RT vial (see step 2). A VIALMIX RFID that is not functioning properly must never be used. Only use a vial activated from a properly functioning VIALMIX RFID. Refer to the VIALMIX RFID User's Guide to ensure that a properly functioning VIALMIX RFID is used.

- Immediately after VIALMIX RFID activation, but no more than 15 minutes, place the activated vial in the upright position and remove the flip top cap. Insert the 13mm ViaLok (Vented Vial Access Device) into the center of the rubber stopper and push down until properly engaged and locked onto the vial.
- Obtain a syringe containing 1.4 mL preservative-free 0.9% Sodium Chloride Injection, USP.
- Attach the syringe containing 1.4 mL preservative-free 0.9% Sodium Chloride Injection, USP to the 13mm ViaLok luer-lok hub. Add 1.4 mL of preservative-free 0.9% Sodium Chloride Injection, USP to the activated DEFINITY RT vial. Do not inject air into the DEFINITY RT vial.
- With the 13mm ViaLok still inserted and syringe attached, rapidly swirl the upright vial for 10 seconds to mix the contents. Activated and diluted DEFINITY RT appears as a milky white homogenous suspension with a presence of foam/bubbles.
- The product must be used within 5 minutes of dilution. If not used within 5 minutes the microspheres should be resuspended by rapidly swirling the upright vial for 10 seconds before the product is withdrawn in a syringe.
- The activated DEFINITY RT may be used for up to 4 hours from the time of dilution, with the 13mm ViaLok still attached, but only after the microspheres are resuspended by rapidly swirling the upright vial for 10 seconds.
- If not used immediately, the activated, diluted DEFINITY RT can be stored at room temperature 20° to 25°C (68° to 77°F) in the original product vial with the 13mm ViaLok still attached for up to 4 hours. A sterile syringe or cap should be attached to the Luer fitting on the ViaLok until use.
- Invert the vial and withdraw the activated milky white suspension through the 13mm ViaLok into the syringe. Do not inject air into the DEFINITY RT vial.
- Use the product immediately after its withdrawal from the vial; do not allow the product to stand in the syringe.
- For bolus dosing, withdraw appropriate volume based on patient weight (kg) for administration. For infusion dosing, dilute 1.3 mL Definity RT in 50 mL of preservative-free 0.9% Sodium Chloride Injection, USP [see Dosage 2.2].

Special Instructions for the DEFINITY RT Radio Frequency Identification (RFID)-Tagged Vial

Full instructions for use of VIALMIX RFID are provided on the VIALMIX RFID screen and User's Guide.

- The RFID tag allows for the exchange of product information such as activation time and activation rate.
- VIALMIX RFID will only activate DEFINITY and DEFINITY RT RFID-tagged vials. Function of the RFID technology is not dependent on vial orientation as it is placed in the VIALMIX RFID. If the RFID tag is damaged or otherwise non-functional, the VIALMIX RFID will notify the user and the vial with the non-functional RFID tag cannot be used to activate DEFINITY RT with VIALMIX RFID. Discard the nonfunctional RFID-tagged DEFINITY RT vial.
- Follow all manufacturers' guidelines and do not operate any part of the VIALMIX RFID with DEFINITY RT RFID-tagged vials within 6 inches (15 cm) of a pacemaker and/or defibrillator.

3 DOSAGE FORMS AND STRENGTHS

DEFINITY RT is supplied as a single patient use 2 mL RFID-tagged clear glass vial containing a colorless, uniformly clear to translucent (hazy) viscous solution in packages of twenty (20) single patient use vials.

Prior to activation, the headspace of each vial contains 6.52 mg/mL octafluoropropane and the viscous solution contains 3.75 mg/mL of a lipid blend. After activation and dilution with 0.9% Sodium Chloride Injection, USP, each vial contains a maximum of 1.2 X 10¹⁰ perflutren lipid microspheres, and about 80 microL/mL (0.65 mg/mL) octafluoropropane [see Description (11)].

4 CONTRAINDICATIONS

Do not administer DEFINITY RT to patients with known or suspected:

- Hypersensitivity to perflutren lipid microsphere or its components, such as polyethylene glycol (PEG) [see Warnings and Precautions (5.2) and Description (11)].

5 WARNINGS AND PRECAUTIONS

5.1 Serious Cardiopulmonary Reactions

Serious cardiopulmonary reactions including fatalities have occurred uncommonly during or shortly following perflutren-containing microsphere administration, typically within 30 minutes of administration. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias). Always have cardiopulmonary resuscitation personnel and equipment readily available prior to DEFINITY RT administration and monitor all patients for acute reactions.

The reported reactions include: fatal cardiac or respiratory arrest, shock, syncope, symptomatic arrhythmias (atrial fibrillation, tachycardia, bradycardia, supraventricular tachycardia, ventricular fibrillation, ventricular tachycardia), hypertension, hypotension, dyspnea, hypoxia, chest pain, respiratory distress, stridor, wheezing, loss of consciousness, and convulsions [see Adverse Reactions (6)].

5.2 Hypersensitivity Reactions

In postmarketing use, serious hypersensitivity reactions were observed during or shortly following perflutren-containing microsphere administration including:

Anaphylaxis, with manifestations that may include death, shock, bronchospasm, throat tightness, angioedema, edema (pharyngeal, palatal, mouth, peripheral, localized), swelling (face, eye, lip, tongue, upper airway), facial hypoesthesia, rash, urticaria, pruritus, flushing, and erythema.

These reactions have occurred in patients with no prior exposure to perflutren-containing microsphere products. DEFINITY RT contains PEG. There may be increased risk of serious reactions including death in patients with prior hypersensitivity reaction(s) to PEG [see Adverse Reactions (6.2) and Description (11)]. Clinically assess patients for prior hypersensitivity reactions to products containing PEG, such as certain colonoscopy bowel preparations and laxatives. Always have cardiopulmonary resuscitation personnel and equipment readily available prior to DEFINITY RT administration and monitor all patients for hypersensitivity reactions.

5.3 Systemic Embolization

When administering DEFINITY RT to patients with a cardiac shunt, the microspheres can bypass filtering by the lung and enter the arterial circulation. Assess patients with shunts for embolic phenomena following DEFINITY RT administration. DEFINITY RT is only for intravenous administration; do not administer DEFINITY RT by intra-arterial injection [see Dosage and Administration (2.1)].

5.4 Ventricular Arrhythmia Related to High Mechanical Index

High ultrasound mechanical index values may cause microsphere cavitation or rupture and lead to ventricular arrhythmias. Additionally, end-systolic triggering with high mechanical indices has been reported to cause ventricular arrhythmias. DEFINITY RT is not recommended for use at mechanical indices greater than 0.8 [see Dosage and Administration (2)].

6 ADVERSE REACTIONS

The following serious adverse reactions are described elsewhere in the labeling:

- Serious Cardiopulmonary Reactions [see Warnings and Precautions (5.1)]
- Hypersensitivity Reactions [see Warnings and Precautions (5.2)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

A total of 1716 subjects were evaluated in pre-market clinical trials of activated DEFINITY. In this group, 1063 (61.9%) were male and 653 (38.1%) were female, 1328 (77.4%) were White, 258 (15.0%) were Black, 74 (4.3%) were Hispanic, and 56 (3.3%) were classified as other racial or ethnic groups. The mean age was 56.1 years (range 18 to 93). Of these, 144 (8.4%) had at least one adverse reaction (Table 1). There were 26 serious adverse events and 15 (0.9%) subjects discontinued because of an adverse event.

Serious Adverse Reactions

Among the 1716 study patients, 19 (1.1%) suffered serious cardiopulmonary adverse reactions.

For all adverse reactions, the overall incidence of adverse experiences was similar for the <65 year age group and the > 65 year age group, similar in males and in females, similar among all racial or ethnic groups, and similar for bolus and infusion dosing. Table 1 summarizes the most common adverse reactions.

Table 1 New-Onset Adverse Reactions Occurring in ≥0.5% of All DEFINITY-Treated Subjects			
		DEFINITY (N=1716)	
Total Number of Adverse Reactions		269	
Total Number of Subjects with an Adverse Reaction		144	(8.4%)
Body system			
Preferred term		n	(%)
Application Site Disorders		11	(0.6)
Injection Site Reactions		11	(0.6)
Body as a Whole		41	(2.4)
Back/renal pain		20	(1.2)
Chest pain		13	(0.8)
Central and peripheral nervous system disorder		54	(3.1)
Headache		40	(2.3)
Dizziness		11	(0.6)
Gastrointestinal system		31	(1.8)
Nausea		17	(1.0)
Vascular (extracardiac) disorders		19	(1.1)
Flushing		19	(1.1)

N=Sample size 1716 subjects who received activated DEFINITY
n=Number of subjects reporting at least one Adverse Reaction

Other adverse reactions that occurred in ≤0.5% of the activated DEFINITY-dosed subjects were:

Body as a Whole: Fatigue, fever, hot flushes, pain, rigors, and syncope

Cardiovascular: Abnormal ECGs, bradycardia, tachycardia, palpitation, hypertension and hypotension

Digestive: Dyspepsia, dry mouth, tongue disorder, toothache, abdominal pain, diarrhea and vomiting

Hematology: Granulocytosis, leukocytosis, leukopenia, and eosinophilia

Musculoskeletal: Arthralgia

Nervous System: Leg cramps, hypertonia, vertigo and paresthesia

Platelet, Bleeding, and Clotting: Hematoma

Respiratory: Coughing, hypoxia, pharyngitis, rhinitis and dyspnea

Special Senses: Decreased hearing, conjunctivitis, abnormal vision and taste perversion

Skin: Pruritus, rash, erythematous rash, urticaria, increased sweating, and dry skin

Urinary: Albuminuria

6.2 Postmarketing Experience

In a prospective, multicenter, open-label registry of 1053 patients receiving DEFINITY in routine clinical practice, heart rate, respiratory rate, and pulse oximetry were monitored for 30 minutes after DEFINITY administration. No deaths or serious adverse reactions were reported, suggesting that these reactions are unlikely to occur at a rate of more than 0.3% when DEFINITY is used according to recommendations.

The following adverse reactions have been identified during the post-marketing use of perflutren and PEG-containing microsphere products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Fatal cardiopulmonary and hypersensitivity reactions and other serious but non-fatal adverse reactions were uncommonly reported. These reactions typically occurred within 30 minutes of DEFINITY administration. These serious reactions may be increased among patients with pre-existing PEG hypersensitivity and/or unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias [see Warnings and Precautions (5.1, 5.2)].

Reported reactions included:

Cardiopulmonary

Fatal cardiac or respiratory arrest, shock, syncope, symptomatic arrhythmias (atrial fibrillation, tachycardia, bradycardia, supraventricular tachycardia, ventricular fibrillation, ventricular tachycardia), hypertension, hypotension, dyspnea, hypoxia, chest pain, respiratory distress, stridor, wheezing.

Hypersensitivity

Anaphylaxis, with manifestations that may include death, shock, bronchospasm, throat tightness, angioedema, edema (pharyngeal, palatal, mouth, peripheral, localized), swelling (face, eye, lip, tongue, upper airway), facial hypoesthesia, rash, urticaria, pruritus, flushing, and erythema.

Neurologic

Coma, loss of consciousness, convulsion, seizure, transient ischemic attack, agitation, tremor, vision blurred, dizziness, headache, fatigue.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Available data from case reports with DEFINITY use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. DEFINITY RT has a very short half-life; therefore, administration of DEFINITY RT to a pregnant woman is not expected to result in clinically relevant fetal exposure. No adverse developmental outcomes were observed in animal reproduction studies with administration of activated DEFINITY in pregnant rats and rabbits during organogenesis at doses up to 8 and 16 times, respectively, the maximum human dose based on body surface area (see Data).

All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data

Animal Data

DEFINITY was administered intravenously to rats at doses of 0.1, 0.3, and 1.0 mL/kg (approximately 0.8, 2.4, and 8 times the recommended maximum human dose based on body surface area); DEFINITY doses were administered daily from day 6 to day 17 of gestation. DEFINITY was administered intravenously to rabbits at doses of 0.1, 0.3, and 1.0 mL/kg (approximately, 1.6, 4.8, and 16 times the recommended maximum human dose based on body surface area); DEFINITY doses were administered daily from day 7 to day 19 of gestation. No significant findings on the fetus were observed.

8.2 Lactation

Risk Summary

There are no data on the presence of DEFINITY in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for DEFINITY RT and any potential adverse effects on the breastfed infant from DEFINITY RT or from the underlying maternal condition.

8.4 Pediatric Use

The safety and effectiveness of activated DEFINITY RT have not been established in the pediatric population.

The safety of injecting activated DEFINITY RT in neonates and infants with immature pulmonary vasculature has not been studied.

The pharmacokinetics of activated DEFINITY RT in pediatric subjects has not been studied.

8.5 Geriatric Use

In clinical trials, the overall incidence of adverse reactions was similar for the <65 year age group and the ≥65 year age group. Of the total number of subjects in clinical trials of DEFINITY, 144 (33%) were 65 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.


11 DESCRIPTION

DEFINITY RT (Perflutren Lipid Microsphere) Injectable Suspension is an ultrasound contrast agent. The DEFINITY RT vial contains components that upon activation and dilution yield


perflutren lipid microspheres. The unactivated vial contains a colorless, uniformly clear to translucent (hazy), viscous, sterile, non-pyrogenic solution, which upon activation with the aid of a VIALMIX RFID and dilution with 0.9% Sodium Chloride Injection, USP, provides a homogeneous, hypertonic, milky white injectable suspension of perflutren lipid microspheres. The suspension of activated DEFINITY RT is administered by intravenous injection.

The perflutren lipid microspheres are composed of octafluoropropane encapsulated in an outer lipid shell consisting of (R) – hexadecanoic acid, 1-[(phosphonoxy)methyl]-1,2-ethanediyl ester, monosodium salt (abbreviated DPPA); (R) - 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-3,4,9-tri-oxa-4-phosphapentacosan-1-aminium, 4-oxide, inner salt (abbreviated DPPC); and (R)-α-[6-hydroxy-6-oxido-9-[(1-oxohexadecyl)oxy]-5,7,11-trioxa-2-aza-6-phosphahexacos-1-yl]-ω-methoxypoly(ox-1,2-ethanediyl), monosodium salt; commonly called N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-di-palmitoyl-sn-glycero-3- phosphatidylethanolamine, monosodium salt (abbreviated MPEG5000 DPPE).


Octafluoropropane is chemically characterized as 1,1,1,2,2,3,3,3- octafluoropropane. It has a molecular weight of 188, empirical formula of C₃F₈ and has the following structural formula:




DPPA has a molecular weight of 670, empirical formula of C₃₅H₅₈O₈PNa, and following structural formula:



DPPC has a molecular weight of 734, empirical formula of C₄₀H₈₀NO₈P, and following structural formula:



MPEG5000 DPPE has an approximate molecular weight of 5750 represented by empirical formula C₂₆₅H₅₂₇NO₁₂₃PNa, contains <100ppm Ca+2 and the following structural formula:



Prior to activation, the DEFINITY RT vial contains 6.52 mg/mL octafluoropropane in the headspace which is confirmed by positive IR spectroscopic testing in every vial. Each mL of the viscous solution contains 3.75 mg lipid blend (consisting of 0.225 mg DPPA, 2.005 mg DPPC, and 1.520 mg MPEG5000 DPPE), 517.5 mg propylene glycol, 631 mg glycerin, 0.370 mg anhydrous sodium acetate, and 0.030 mg glacial acetic acid. The pH is 5.2 to 6.4. DEFINITY RT does not contain bacterial preservative.

After activating the contents of the vial in a VIALMIX RFID and diluting with 1.4 mL of preservative-free 0.9% Sodium Chloride, Injection, USP, each mL of the milky white suspension contains 0.045 mg DPPA, 0.401 mg DPPC, 0.304 mg MPEG5000 DPPE, 0.074 mg anhydrous sodium acetate, 0.006 mg glacial acetic acid, a maximum of 1.2 X 10¹⁰ perflutren lipid microspheres, and about 80 microL/mL (0.65 mg/mL) octafluoropropane. The microsphere particle size parameters are listed in Table 2 below:

Table 2 Microsphere Size Distribution	
Microsphere particle size parameters	
Mean diameter range	1.1 µm – 3.3 µm
Percent less than 10 µm	98%
Maximum diameter	20 µm

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Perflutren lipid microspheres exhibit lower acoustic impedance than blood and enhance the intrinsic backscatter of blood. These physical acoustic properties of activated DEFINITY RT provide contrast enhancement of the left ventricular chamber and aid delineation of the left ventricular endocardial border during echocardiography.

In animal models the acoustic properties of activated DEFINITY were established at or below a mechanical index of 0.7 (1.8 MHz frequency). In clinical trials, the majority of the patients were imaged at or below a mechanical index of 0.8.

12.3 Pharmacokinetics

Human pharmacokinetics information is not available for the intact or degassed lipid microspheres. The pharmacokinetics of octafluoropropane gas (OFP) was evaluated in healthy subjects (n=8) after the intravenous administration of activated DEFINITY at a 50 microL/kg dose.

Distribution

OFP gas binding to plasma proteins or partitioning into blood cells has not been studied. However, OFP protein binding is expected to be minimal due to its low partition coefficient into whole blood.

Metabolism

OFP is a stable gas that is not metabolized. The phospholipid components of the microspheres are thought to be metabolized to free fatty acids.

Elimination

OFP was not detectable after 10 minutes in most subjects either in the blood or in expired air. OFP concentrations in blood were shown to decline in a mono-exponential fashion with a mean half-life of 1.3 minutes in healthy subjects.

Special Populations

The pharmacokinetics of octafluoropropane gas (OFP) was evaluated in subjects (n=11) with chronic obstructive pulmonary disease (COPD). The mean half-life of OFP in blood was 1.9 minutes. The total lung clearance of OFP was similar to that in healthy subjects.

The pharmacokinetics of activated DEFINITY RT has not been studied in subjects with hepatic diseases or congestive heart failure.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility

Studies with activated DEFINITY have not been performed to evaluate carcinogenic potential. Evidence of genotoxicity was not found in the following studies with activated DEFINITY:

1) bacterial mutagenesis assay (Ames assay), 2) *in vitro* mammalian mutagenesis assay, 3) *in vitro* human lymphocyte chromosome aberration assay, and 4) *in vivo* rat micronucleus assay.

Impairment of male or female fertility was not observed in rats and rabbits treated with activated DEFINITY at doses up to 24 and 15 times the human dose based on body surface area (in rats and rabbits respectively).

14 CLINICAL STUDIES

14.1 Echocardiography

A total of 249 subjects were evaluated in clinical trials (208 received activated DEFINITY and 41 placebo). In this group, 154 (61.8%) were male and 95 (38.2%) were female; 183 (73.5%) were White, 38 (15.3%) were Black, 21 (8.4%) were Hispanic, and 7 (2.8%) were classified as other racial or ethnic groups. The mean age was 53.9 years (range 18 to 87).

Activated DEFINITY was evaluated in four controlled clinical trials: Two open-label baseline controlled, unpaired blinded image evaluation studies and two identical placebo-controlled, unpaired blinded image evaluation studies. Subjects were eligible for these studies if they had two or more (of six) non-evaluable segments in either the apical 2- or 4-chamber view in non-contrast fundamental echocardiography.

In the baseline controlled studies, a total of 126 (67 in study A and 59 in study B) subjects received a bolus dose of 10 microL/kg activated DEFINITY. The outcome measures in these studies included the blinded assessment of ejection fraction (EF), endocardial border length (EBL) obtained by direct measurement, and qualitative assessment of wall motion.

In the two placebo-controlled studies a total of 123 subjects were randomized in 1:2 ratio to receive two intravenous bolus doses of either 0.9% Sodium Chloride Injection, USP (placebo) or activated DEFINITY 10 microL/kg (17 placebo vs. 33 activated DEFINITY patients and 24 placebo vs. 49 activated DEFINITY patients, respectively). The outcome measure for assessing the effectiveness of activated DEFINITY was the blinded assessment of improvement in ventricular chamber enhancement (measured by videodensitometry at end-diastole and end-systole).

Endocardial Border Length

As shown in Table 3, compared to baseline, a single bolus dose of 10 microL/kg of activated DEFINITY increased the length of endocardial border that could be measured at both end-systole and end-diastole. The mean change in border length from baseline at end-diastole was statistically significant for all readers in the apical 4-chamber view and for 3 out of 4 readers for the apical 2-chamber view. The mean change in border length from baseline at end-systole was statistically significant for 3 out of 4 readers for the apical 4-chamber view and for 2 out of 4 readers for the apical 2-chamber view.

Ventricular Chamber Enhancement

Left ventricular chamber enhancement after an activated DEFINITY dose of 10 microL/kg was significantly increased from baseline compared to placebo in both views at the mid-ventricular and apical levels at end-diastole. Similar results were noted at end-systole, with the exception of the 4-chamber view.

Wall Motion

In a retrospective analysis, in a subset of subjects (n=12 to 47, depending on reader) having at least 2 adjacent segments non-evaluable on non-contrast imaging, activated DEFINITY

converted a baseline non-evaluable image to an evaluable image in 58 to 91% of the patients, depending on the reader. In the converted images, the accuracy of wall motion (i.e., normal versus abnormal) improved in 42 to 71% of the patients, depending on the reader, however, improvement in the specific diagnostic accuracy (e.g., hypokinetic, akinetic etc.) was not established. Also, in 13 to 37% of the patients, depending on the reader, activated DEFINITY was found to obscure the wall motion rendering the image non-evaluable.

Ejection Fraction

In the 2 baseline controlled studies, ejection fraction results were evaluated in comparison to MRI. The results were evaluated by 3 blinded, independent radiologists. In these studies, although there was a statistically significant increase in ventricular chamber enhancement, activated DEFINITY did not significantly improve the assessment of ejection fraction compared to the baseline images.

Table 3 MEAN (SD) ENDOCARDIAL BORDER LENGTH (CM) BY BOTH APICAL 2- AND 4-CHAMBER VIEWS AT END-SYSTOLE AND END-DIASTOLE BY STUDY, EVALUABLE SUBJECTS

Study/View	Endocardial Border Length – Blinded Read			
	Mean(SD) at End-Diastole		Mean(SD) at End-Systole	
	Reader 1	Reader 2	Reader 1	Reader 2
Study A: (N = 67)				
Apical 2-chamber				
Baseline	8.0(3.4)	4.7(2.8)	7.1(3.3)	4.3(2.6)
Post-DEFINITY RT	12.8(5.2)*	5.8(2.6)*	10.6(5.0)*	4.4(2.3)
Apical 4-chamber				
Baseline	8.1(3.3)	4.5(2.6)	7.6(3.2)	4.5(2.7)
Post-DEFINITY RT	13.5(5.2)*	6.8(3.3)*	11.5(4.4)*	5.3(3.1)
Study B: (N = 59)				
Apical 2-chamber				
Baseline	4.3(2.6)	7.8(5.3)	4.1(2.4)	6.5(5.1)
Post-DEFINITY RT	5.7(4.7)*	8.2(6.5)	5.5(4.4)*	6.9(6.3)
Apical 4-chamber				
Baseline	4.0(2.7)	9.2(5.9)	3.8(2.6)	7.3(5.6)
Post-DEFINITY RT	7.1(5.5)*	11.5(7.5)*	5.9(5.3)*	8.7(6.3)*
Activated DEFINITY Bolus Dose = 10 µL/kg				
* Significant change from baseline (paired t-test, p<0.05)				

In an open administration, crossover trial, 64 patients were randomized to receive both bolus (10 microL/kg) and infusion (1.3 mL activated DEFINITY in 50 mL 0.9% Sodium Chloride Injection, USP at the rate of 4 mL/min) dosing of activated DEFINITY. Outcome measures for this study included clinically useful ventricular cavity enhancement and endocardial border length. Similar results were seen as described above.

Optimal activated DEFINITY doses and device settings for harmonic imaging have not been established.

14.2 Pulmonary Hemodynamic Effects

The impact of DEFINITY on pulmonary hemodynamics was explored in a prospective, open-label study of patients with normal (≤ 35 mmHg, 16 patients) and elevated (> 35 mmHg, ≤ 75 mmHg, 16 patients) pulmonary artery systolic pressure undergoing right heart catheterization. Patients with pulmonary artery systolic pressure greater than 75 mmHg were excluded from this study. Systemic hemodynamic parameters and ECGs were also evaluated. No clinically important pulmonary hemodynamic, systemic hemodynamic, or ECG changes were observed. This study did not assess the effect of DEFINITY on visualization of cardiac or pulmonary structures.

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

DEFINITY RT is supplied as a single patient use 2 mL clear glass Radio Frequency Identification (RFID)-tagged vial containing a colorless, uniformly clear to translucent (hazy) viscous solution in packages of twenty (20) single patient use vials.

- One (1) 2 mL RFID-tagged vial - NDC (11994-017-01)
- Twenty (20) 2 mL RFID-tagged vials per kit - NDC (11994-017-20)

16.2 Storage and Handling

Store at Room Temperature 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

Regarding interference with medical devices, the RFID tag and VIALMIX RFID unit meets the IEC 60601-1-2 requirements for emission and immunity standards for medical devices.

17 PATIENT COUNSELING INFORMATION

Advise patients to inform their healthcare provider if they develop any symptoms of hypersensitivity after DEFINITY RT administration, including rash, wheezing, or shortness of breath.

Distributed By
Lantheus Medical Imaging
331 Treble Cove Road
N. Billerica, Massachusetts 01862 USA



For ordering, call toll free: 800-299-3431 • All Other Business: 800-362-2668
(For Massachusetts and International, call: 978-667-9531)

Patent: <http://www.lantheus.com/patents/index.html>